Learning Objectives

After completion of this module, you should be able to:

  • Recognize the different causes of eczema including the differential diagnosis of atopic dermatitis (AD) and score severity of AD
  • Describe the different forms of treatment for AD
  • Identify the side effects of topical therapies
  • Discuss systemic therapeutics that are available for AD and their adverse effects, including oral immunosuppressive agents such as oral corticosteroids
     

Start Date: June 1, 2016
End Date: November 30, 2022

Faculty & Disclosures

Luz  Fonacier, MD, FACAAI: Genentech- Research Grant; Regeneron - Research Grant, Advistory Board; Shire - Research Grant; Pfizer - Research Grant; AbbVie - Advisory Board

Mark Boguniewicz, MD, FACAAI: Anacor – Research Grant, Celgene, Regeneron – Advisory Board 

Peter Lio: Pfizer- Advisory Board, Speaker; Regeneron/Sanofi Genzyme- Investigator, Advisory Board, Speaker; AbbVie- Invesitgator, Advisory Board; Altus Labs- Advisory Board, Stock Options; AOBiome- Advisor, Investigator; Dermavant Sciences- Advisory Board; Dermira- Advisory Board; Eli Lilly- Advisory Board, Consultant; Galderma- Advisory Board; IntraDerm- Advisory Board; Johnson & Johnson- Advisory Board; Kiniksa- Consultant; La Roche-Posay/L’Oreal- Speaker, Advisory Board; Menlo Therapeutics- Advisory Board; Micreos Human Health- Advisory Board, Stock Options; Pierre-Fabre- Speaker, Advisory Board; Realm Therapeutics- Advisory Board; Syncere Skin Systems- Advisory Board, Stock Options; Theraplex- Consultant, Patent Pending, Residual for specific product not yet for sale.

Peck Ong, MD, FACAAI: Atopic dermatitis Research Network- Research Grant; Tioga – Research Grant; Regeneron – Advisory Board.

Gerald B. Lee, MD: Nothing to Disclose

CME Statement

Accreditation

The American College of Allergy, Asthma & Immunology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology designates this PI CME activity for a maximum of 20 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.